Cargando…

Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial

Detalles Bibliográficos
Autores principales:	Platzbecker, U, Sekeres, M A, Kantarjian, H, Giagounidis, A, Mufti, G J, Jia, C, Yang, A S, Fenaux, P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274610/ https://www.ncbi.nlm.nih.gov/pubmed/25179731 http://dx.doi.org/10.1038/leu.2014.253

Ejemplares similares

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia
por: Giagounidis, Aristoteles, et al.
Publicado: (2014)

Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long‐term safety and efficacy
por: Fenaux, Pierre, et al.
Publicado: (2017)

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes
por: Giagounidis, Aristoteles, et al.
Publicado: (2008)

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
por: Komrokji, Rami S., et al.
Publicado: (2022)

Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
por: Sekeres, M A, et al.
Publicado: (2014)

Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
por: Santini, Valeria, et al.
Publicado: (2020)

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
por: Platzbecker, U, et al.
Publicado: (2013)

Differences in genomic patterns and clinical outcomes between African-American and White patients with myelodysplastic syndromes
por: Nazha, A, et al.
Publicado: (2017)

Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes
por: Giagounidis, Aristoteles, et al.
Publicado: (2013)

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts
por: Zeidan, Amer M., et al.
Publicado: (2022)

Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms – results of the EUROPE trial by EMSCO
por: Kubasch, Anne Sophie, et al.
Publicado: (2022)

The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
por: Sekeres, Mikkael A., et al.
Publicado: (2018)

PB2014: A PHASE 2/3 TRIAL OF ORAL AZACITIDINE IN PATIENTS WITH LOW- OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES
por: Garcia-Manero, Guillermo, et al.
Publicado: (2023)

Safety and Efficacy of Eltrombopag and Romiplostim in Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis
por: Meng, Fanqiao, et al.
Publicado: (2020)

Sequential Use of Efgartigimod and Romiplostim Restored Platelet Response in Two Multi-Refractory Thrombocytopenic Patients, Previously Treated with Thrombopoietin Receptor Agonists
por: Carpenedo, Monica, et al.
Publicado: (2023)

Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes
por: Zeidner, Joshua F., et al.
Publicado: (2022)

Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial
por: Garcia-Manero, Guillermo, et al.
Publicado: (2022)

New synergistic efficacy of combination of romiplostim and steroid in refractory immune thrombocytopenia patients
por: Yoon, Jun Seok, et al.
Publicado: (2018)

Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial
por: Kubasch, A. S., et al.
Publicado: (2023)

Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial
por: Oliva, Esther Natalie, et al.
Publicado: (2021)

Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2023)

Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burden
por: Oelschlaegel, U, et al.
Publicado: (2016)

Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care
por: Nazha, Aziz, et al.
Publicado: (2017)

Recovery of Bone Marrow Function in VEXAS Syndrome-potential Role for Romiplostim
por: Al-Hakim, Adam, et al.
Publicado: (2023)

Preclinical modeling of myelodysplastic syndromes
por: Rouault-Pierre, K, et al.
Publicado: (2017)

VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder
por: Huang, Huijun, et al.
Publicado: (2021)

Romiplostim plus danazol as salvage treatment for eltrombopag refractory immune thrombocytopenia: a retrospective pilot study
por: Nam, Chang Hyun, et al.
Publicado: (2021)

Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin
por: Wang, Chen, et al.
Publicado: (2021)

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents
por: Duchmann, M, et al.
Publicado: (2017)

When karyotype is decisive for myelodysplastic syndromes diagnosis
por: Perazzio, Aline dos Santos Borgo, et al.
Publicado: (2019)

Myelodysplastic syndromes and idiopathic pulmonary fibrosis: a dangerous liaison
por: Papiris, Spyros A., et al.
Publicado: (2019)

Should we reconsider platelet content criteria for single donor platelets in West Bengal, India?
por: Javed, Rizwan, et al.
Publicado: (2017)

Megaloblastic Anemia with Ring Sideroblasts is not Always Myelodysplastic Syndrome
por: Narang, Neha Chopra, et al.
Publicado: (2016)

Characterization of Serous Cell-Free DNA in Myelodysplastic Syndromes
por: Zhu, Hongbo, et al.
Publicado: (2022)

Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts
por: Platzbecker, Uwe, et al.
Publicado: (2023)

Myelodysplastic Syndrome Associated With Auto-Immune Inflammatory Disease in VEXAS Syndrome
por: Thomas, Vibha Taneja, et al.
Publicado: (2021)

Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes
por: Brecqueville, M, et al.
Publicado: (2011)

Dissecting the cell of origin of aberrant SALL4 expression in myelodysplastic syndrome
por: Tatetsu, Hiro, et al.
Publicado: (2023)

CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q)
por: Bello, Erica, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_37k22dh65o5l18ma79angn1ppu